Inhibition of FAAH confers increased stem cell migration via PPARα

Di Marzo, 2007, Endocannabinoids and the regulation of their levels in health and disease, Curr. Opin. Lipidol., 18, 129, 10.1097/MOL.0b013e32803dbdec Pertwee, 2014, Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications, Proc. Nutr. Soc., 73, 96, 10.1017/S0029665113003649 Deutsch, 1993, Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist, Biochem. Pharmacol., 46, 791, 10.1016/0006-2952(93)90486-G Blankman, 2007, A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol, Chem. Biol., 14, 1347, 10.1016/j.chembiol.2007.11.006 Saghatelian, 2004, Assignment of endogenous substrates to enzymes by global metabolite profiling, Biochemistry., 43, 14332, 10.1021/bi0480335 Ahern, 2003, Activation of TRPV1 by the satiety factor oleoylethanolamide, J. Biol. Chem., 278, 30429, 10.1074/jbc.M305051200 Ambrosino, 2013, Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide, Br. J. Pharmacol., 168, 1430, 10.1111/bph.12029 Wisnoskey, 2003, Activation of vanilloid receptor type I in the endoplasmic reticulum fails to activate store-operated Ca2+ entry, Biochem. J., 372, 517, 10.1042/bj20021574 Zygmunt, 2013, Monoacylglycerols activate TRPV1–a link between phospholipase C and TRPV1, PLoS One., 8, e81618, 10.1371/journal.pone.0081618 Fu, 2003, Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha, Nature., 425, 90, 10.1038/nature01921 Guzmán, 2004, Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), J. Biol. Chem., 279, 27849, 10.1074/jbc.M404087200 Kozak, 2002, 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist, J. Biol. Chem., 277, 23278, 10.1074/jbc.M201084200 Lo Verme, 2005, The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide, Mol. Pharmacol., 67, 15, 10.1124/mol.104.006353 Romano, 2012, Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery, Eur. J. Pharmacol., 683, 197, 10.1016/j.ejphar.2012.02.049 Sun, 2007, Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism, Br. J. Pharmacol., 152, 734, 10.1038/sj.bjp.0707478 Sun, 2006, Cannabinoids and PPARalpha signalling, Biochem. Soc. Trans., 34, 1095, 10.1042/BST0341095 Jhaveri, 2008, Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain, Neuropharmacology., 55, 85, 10.1016/j.neuropharm.2008.04.018 Justinova, 2015, Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse, Neuropsychopharmacology., 40, 2185, 10.1038/npp.2015.62 Luchicchi, 2010, Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors, Addict. Biol., 15, 277, 10.1111/j.1369-1600.2010.00222.x Mazzola, 2009, Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors, Learn. Mem., 16, 332, 10.1101/lm.1145209 Sagar, 2008, Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain, Br. J. Pharmacol., 155, 1297, 10.1038/bjp.2008.335 Izzo, 2009, Cannabinoids in intestinal inflammation and cancer, Pharmacol. Res., 60, 117, 10.1016/j.phrs.2009.03.008 Kozono, 2010, Involvement of the endocannabinoid system in periodontal healing, Biochem. Biophys. Res. Commun., 394, 928, 10.1016/j.bbrc.2010.03.080 Whyte, 2009, The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo., Proc. Natl. Acad. Sci. USA., 106, 16511, 10.1073/pnas.0902743106 Yu, 2010, The cannabinoid receptor type 2 is time-dependently expressed during skeletal muscle wound healing in rats, Int. J. Legal Med., 124, 397, 10.1007/s00414-010-0465-1 Idris, 2010, Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies, Curr. Neuropharmacol., 8, 243, 10.2174/157015910792246173 Ofek, 2006, Peripheral cannabinoid receptor, CB2, regulates bone mass, Proc. Natl. Acad. Sci. USA., 103, 696, 10.1073/pnas.0504187103 Tam, 2008, The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling, FASEB J., 22, 285, 10.1096/fj.06-7957com Lastres-Becker, 2006, An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments, Curr. Med. Chem., 13, 3705, 10.2174/092986706779026156 Zhang, 2010, Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator, Br. J. Pharmacol., 160, 1583, 10.1111/j.1476-5381.2010.00841.x Yang, 2010, Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells, Exp. Eye Res., 91, 462, 10.1016/j.exer.2010.06.022 Wright, 2005, Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing, Gastroenterology., 129, 437, 10.1016/j.gastro.2005.05.026 Schmuhl, 2014, Increase of mesenchymal stem cell migration by cannabidiol via activation of p42/44 MAPK, Biochem. Pharmacol., 87, 489, 10.1016/j.bcp.2013.11.016 Huang, 2010, Genetic modification of viability, migration, engraftment, and capillary density in the injured myocardium, Circ. Res., 106, 1753, 10.1161/CIRCRESAHA.109.196030 Qin, 2014, Mesenchymal stem cells: mechanisms and role in bone regeneration, Postgrad. Med. J., 90, 643, 10.1136/postgradmedj-2013-132387 Walker, 2010, Unique precursors for the mesenchymal cells involved in injury response and fibrosis, Proc. Natl. Acad. Sci. USA., 107, 13730, 10.1073/pnas.0910382107 Shoji, 2010, Local transplantation of human multipotent adipose-derived stem cells accelerates fracture healing via enhanced osteogenesis and angiogenesis, Lab. Invest., 90, 637, 10.1038/labinvest.2010.39 Yao, 2013, Reversing bone loss by directing mesenchymal stem cells to the bone, Stem Cells., 31, 2003, 10.1002/stem.1461 Aguado, 2005, The endocannabinoid system drives neural progenitor proliferation, FASEB J., 19, 1704, 10.1096/fj.05-3995fje Goncalves, 2008, A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner, Mol. Cell. Neurosci., 38, 526, 10.1016/j.mcn.2008.05.001 Rashid, 2013, N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation, J. Neurochem., 125, 869, 10.1111/jnc.12255 Xie, 2012, Silencing or amplification of endocannabinoid signaling in blastocysts via CB1 compromises trophoblast cell migration, J. Biol. Chem., 287, 32288, 10.1074/jbc.M112.381145 Bab, 2011, Skeletal lipidomics: regulation of bone metabolism by fatty acid amid hydrolase family, Br. J. Pharmacol., 163, 1441, 10.1111/j.1476-5381.2011.01474.x Sophocleous, 2011, The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation, Endocrinology., 152, 2141, 10.1210/en.2010-0930 Gao, 2009, Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium, Stem Cells., 27, 857, 10.1002/stem.23 Yun, 2009, Thromboxane A2 modulates migration, proliferation, and differentiation of adipose tissue-derived mesenchymal stem cells, Exp. Mol. Med., 41, 17, 10.3858/emm.2009.41.1.003 Ahn, 2007, Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity, Biochemistry., 46, 13019, 10.1021/bi701378g Alexander, 2005, Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes, Chem. Biol., 12, 1179, 10.1016/j.chembiol.2005.08.011 Mor, 2004, Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies, J. Med. Chem., 47, 4998, 10.1021/jm031140x Bisogno, 1998, Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase, Biochem. Biophys. Res. Commun., 248, 515, 10.1006/bbrc.1998.8874 Ivanov, 2015, A simple method for simultaneous determination of N-arachidonoylethanolamine, N-oleoylethanolamine, N-palmitoylethanolamine and 2-arachidonoylglycerol in human cells, Anal. Bioanal. Chem., 407, 1781, 10.1007/s00216-014-8384-5 Ramer, 2008, Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1, J. Natl. Cancer Inst., 100, 59, 10.1093/jnci/djm268 Xu, 2002, RU486 antagonizes the inhibitory effect of peroxisome proliferator-activated receptor alpha on interleukin-6 production in vascular endothelial cells, J. Steroid Biochem. Mol. Biol., 81, 141, 10.1016/S0960-0760(02)00055-9 Song, 2000, CB1 cannabinoid receptor-mediated cell migration, J. Pharmacol. Exp. Ther., 294, 204 Burns, 2007, Modulation of PPAR activity via phosphorylation, Biochim. Biophys. Acta., 1771, 952, 10.1016/j.bbalip.2007.04.018 Shalev, 1996, The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin, Endocrinology., 137, 4499, 10.1210/endo.137.10.8828512 Juge-Aubry, 1999, Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain, J. Biol. Chem., 274, 10505, 10.1074/jbc.274.15.10505 Rotman, 2010, PPAR modulation of kinase-linked receptor signaling in physiology and disease, Physiology (Bethesda)., 25, 176 Werner, 2014, The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis, Br. J. Pharmacol., 171, 2685, 10.1111/bph.12608 Hornung, 2001, Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis, J. Clin. Endocrinol. Metab., 86, 3108 Stephen, 2013, PPAR ligands decrease human airway smooth muscle cell migration and extracellular matrix synthesis, Eur. Respir. J., 41, 425, 10.1183/09031936.00145009 Goetze, 2002, PPAR activators inhibit endothelial cell migration by targeting Akt, Biochem. Biophys. Res. Commun., 293, 1431, 10.1016/S0006-291X(02)00385-6